Testing treatment response in gallbladder cancer patients
Part of Cancer, Digestive system clinical trials.
This trial studies how gallbladder cancer responds to treatment. It is for people newly diagnosed who have confirmed cancer in biopsy results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with gallbladder cancer confirmed by biopsy (histology).
- You have not received cancer treatment yet (treatment naïve).
- Your diagnosis includes clear lab/biopsy proof of cancer (no confirmed malignancy).
- You are not pregnant.
- You are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This trial is studying people with gallbladder cancer, abnormal cell changes (dysplasia), or gallstones. It aims to learn more about these conditions, possibly before or after treatment, or before gallbladder removal surgery.
This trial looks at how well a modern genetic test (next-generation sequencing) works when analyzing tissue samples from people with bile duct cancer. The goal is to see if this test can help doctors better understand these tumors.
This Phase 2 trial tests a targeted treatment (GEMOX) given after gallbladder cancer surgery. It uses a blood test that looks for cancer-related DNA to monitor recurrence and guide care, aiming to improve outcomes for people with higher-risk disease.
This study looks at using a genetic test (next-generation sequencing) to find cancer gene changes in stage IV hepatobiliary cancer. If there is a matching approved medicine, the study follows how well the “right drug for the right mutation” helps patients receiving palliative care.
This study looks at small DNA pieces in blood to help monitor and guide cancer therapy decisions. It may help the research team understand how these blood markers relate to treatment planning for advanced cancer.
Hear when a new Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.